Structure via PubChem · Public domain (PubChem)
abiraterone acetate
Sign in to savechemical compound
Chemical data
- Formula
- C26H33NO2
- Molecular weight
- 391.5 g/mol
- IUPAC name
- [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
- SMILES
- CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
- InChIKey
- UVIQSJCZCSLXRZ-UBUQANBQSA-N
- XLogP
- 5.2
- Polar surface area
- 39.2 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2011
- Admin. routes
- oral
- Indications
- prostate carcinoma, prostate adenocarcinoma, metastatic prostate cancer, liver disease
via ChEMBL · EBI
Research
1,753 papers- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.The Lancet. Oncology · 2019
- Abiraterone acetate.Drugs in R&D · 2010
- Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial.European urology oncology · 2025
- Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.Drugs of today (Barcelona, Spain : 1998) · 2019
- Abiraterone acetate in the treatment of prostate cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2018
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- abiraterone
- Mass
- 391.25112929600004
Show 4 more facts
- isomeric SMILES
- CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
- chemical formula
- C₂₆H₃₃NO₂
- canonical SMILES
- CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
- Commons category
- Abiraterone acetate
Sources (6)
via Wikidata · CC0